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Methods
Evaluation of the transition to a fixed-dose prothrombin complex 
concentrate regimen at a tertiary regional medical center
John Mullen, PharmD, Lance McNab, PharmD
Inpatient Pharmacy Services, St. Cloud Hospital, St. Cloud, Minnesota
Background Results
Objectives  
• Prothrombin complex concentrate (PCC) for the reversal of vitamin K 
antagonists (VKA) induced anticoagulation was approved for use in the 
US in 2013.1 National guidelines recommend PCC over fresh frozen 
plasma for rapid reversal of anticoagulation in patients with VKA-
associated major bleeding.2
• Approved dosing for PCC is based on pre-treatment INR and body 
weight.1 Other dosing strategies, including fixed-dose protocols utilizing 
doses lower than manufacturer recommendations, have been found to 
be effective.  No dosing strategy has proven to be superior to another.
• In November of 2014, St. Cloud Hospital implemented an order set that 
included PCC orders for warfarin reversal to encourage consistent use 
among providers.  
• In September of 2016, all PCC orders, including those on the reversal 
order set, were changed to a fixed-dose of PCC for warfarin reversal.
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• Evaluate order set use in patients that received PCC for emergent 
warfarin reversal in the emergency department both before and after 
implementation of a fixed-dose protocol
• Evaluate INR response to administration of PCC pre- and post-
implementation and the percentage of post-infusion INRs that were less  
than 2 and 1.5




• IRB-approved, retrospective chart review
• Trial periods:
• August 1, 2015 through July 31, 2016
• November 1, 2016 through October 31, 2017
Analysis
• Continuous variables were assessed using Student’s t-tests 
• Categorical variables were assessed using χ2 tests
Inclusion Criteria Exclusion Criteria
≥ 18 years Not receiving warfarin
PCC for emergent warfarin 
reversal in ED
Did not receive indicated dose
INR not recorded or not 
recorded within 12 hours 
postdose
Patient Characteristics Pre Post P-value
Age (mean, SD) 73.9 (13.6) 76.7 (9.7) 0.18
Weight (kg, mean, SD) 86.6 (24.5) 88.3 (23.1) 0.39
Sex (% male) 63.3% 61.8% 0.9
Presenting INR (mean, SD) 3.64 (2.37) 3.61 (2.24) 0.48
Post INR (mean, SD) 1.23 (0.17) 1.37 (0.17) 0.001
Dose (units, mean, SD) 2454 (732) 1611 (97) < 0.001
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• The pre-implementation group more frequently achieved an INR < 1.5 
compared to the post-implementation group (p = 0.02).  The average INR 
was less than 1.5 in both groups, but significantly higher in the post-
implementation group.
• The average cost of therapy was significantly less in the post-
implementation group.  The total acquisition costs of PCC were 
$117,055.80 and $87,100.20.
• Order set use was similar in both groups.  No patient in the post-
implementation group received an additional 500 unit dose.  Patients in 









*Rounded to nearest vial size





Pre: 30 Post: 34
82 Excluded
65 received outside the ED
8 had INR recorded >12 hrs
4 without a post INR 
3 received unapproved dose
2 not on warfarin
• The mean weight of patients who did not achieve an INR of < 1.5 was 
92.4 kg in the post-group compared to 86.6 kg in the pre-group (p = 0.28)
• Order set use was similar in both groups (60% in pre-group vs 55.9% in 
post-group, p = 0.74)
• Time from presenting INR to PCC administration was 1.45 hours (SD = 
2.37) and 1.53 hours (SD = 2.24), respectively (p = 0.41)
• Time from PCC administration to post INR was 2.24 hours (SD = 0.17) 







































Achieved INR <2 Achieved INR <1.5
Assessment of INR after 1 Dose of PCC
Pre Post
p < 0.001
